House debates

Wednesday, 8 March 2023

Statements by Members

Pharmaceutical Benefits Scheme: Fiasp

1:46 pm

Photo of Ted O'BrienTed O'Brien (Fairfax, Liberal Party, Shadow Minister for Climate Change and Energy) Share this | | Hansard source

As an 11-month-old little baby girl, Freya Goldston was diagnosed with type 1 diabetes. She is now 14, and she came and saw me with her mum Jackie last week. For some years now she has been using an insulin drug called Fiasp and it has been life changing, especially at school and with her sport, because it kicks in so quickly. But the federal government has now delisted Fiasp off the Pharmaceutical Benefits Scheme, off the PBS, having the most dramatic impact on Freya. Freya's family has been paying about $7 a script. They received advice, and it looks like they will now be having to pay around $280 per script for this drug. They found out, by the way, through a blog, social media, which goes to the zero consultation on the part of the government with this.

I talk about Freya, for a good reason. I have met her. She has told me her story. But here is the thing: Freya is just one of 15,000 people across this country for whom Fiasp has been stripped away off the PBS. The government and the minister must act.